Zhengye Biotechnology (ZYBT) Competitors $5.40 -1.62 (-23.08%) As of 03/27/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock ZYBT vs. PAHC, ZYME, EOLS, PHVS, AVDL, OCS, DAWN, COGT, XERS, and GYREShould you be buying Zhengye Biotechnology stock or one of its competitors? The main competitors of Zhengye Biotechnology include Phibro Animal Health (PAHC), Zymeworks (ZYME), Evolus (EOLS), Pharvaris (PHVS), Avadel Pharmaceuticals (AVDL), Oculis (OCS), Day One Biopharmaceuticals (DAWN), Cogent Biosciences (COGT), Xeris Biopharma (XERS), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Zhengye Biotechnology vs. Phibro Animal Health Zymeworks Evolus Pharvaris Avadel Pharmaceuticals Oculis Day One Biopharmaceuticals Cogent Biosciences Xeris Biopharma Gyre Therapeutics Phibro Animal Health (NASDAQ:PAHC) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Is PAHC or ZYBT more profitable? Phibro Animal Health has a net margin of 1.75% compared to Zhengye Biotechnology's net margin of 0.00%. Phibro Animal Health's return on equity of 25.35% beat Zhengye Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Phibro Animal Health1.75% 25.35% 6.21% Zhengye Biotechnology N/A N/A N/A Do analysts rate PAHC or ZYBT? Phibro Animal Health presently has a consensus target price of $21.00, suggesting a potential downside of 3.14%. Given Phibro Animal Health's stronger consensus rating and higher possible upside, equities analysts plainly believe Phibro Animal Health is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 2 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders hold more shares of PAHC or ZYBT? 99.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, PAHC or ZYBT? Phibro Animal Health has higher revenue and earnings than Zhengye Biotechnology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhibro Animal Health$1.11B0.79$2.42M$0.4845.17Zhengye Biotechnology$189.75M1.34N/AN/AN/A Does the media favor PAHC or ZYBT? In the previous week, Phibro Animal Health had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 7 mentions for Phibro Animal Health and 4 mentions for Zhengye Biotechnology. Phibro Animal Health's average media sentiment score of 1.13 beat Zhengye Biotechnology's score of 0.36 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor PAHC or ZYBT? Phibro Animal Health received 316 more outperform votes than Zhengye Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformPhibro Animal HealthOutperform Votes31659.96% Underperform Votes21140.04% Zhengye BiotechnologyN/AN/A SummaryPhibro Animal Health beats Zhengye Biotechnology on 11 of the 12 factors compared between the two stocks. Remove Ads Get Zhengye Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYBT vs. The Competition Export to ExcelMetricZhengye BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$331.11M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E RatioN/A7.2023.1419.03Price / Sales1.34226.01385.7893.17Price / CashN/A65.6738.1634.64Price / BookN/A6.476.934.33Net IncomeN/A$141.90M$3.20B$247.06M7 Day Performance10.66%-3.20%-2.30%-0.37%1 Month Performance28.27%-5.64%2.86%-3.85%1 Year PerformanceN/A-7.47%10.66%1.27% Zhengye Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYBTZhengye BiotechnologyN/A$5.40-23.1%N/AN/A$331.11M$189.75M0.00278News CoverageHigh Trading VolumePAHCPhibro Animal Health3.9534 of 5 stars$21.62-1.1%$21.00-2.9%+66.0%$875.68M$1.11B45.041,860Analyst DowngradeShort Interest ↓Positive NewsZYMEZymeworks2.6648 of 5 stars$12.34-1.9%$21.00+70.2%+21.5%$858.58M$76.30M-8.23460Insider TradePositive NewsEOLSEvolus3.9948 of 5 stars$13.28-2.3%$24.67+85.7%-12.6%$844.44M$266.27M-14.59170PHVSPharvaris1.4403 of 5 stars$15.96-3.3%$40.50+153.8%-33.7%$834.55MN/A-5.7030Gap UpAVDLAvadel Pharmaceuticals3.3628 of 5 stars$8.63-2.4%$19.88+130.3%-51.8%$833.91M$169.12M-10.9270Positive NewsOCSOculis1.9889 of 5 stars$18.97+0.7%$29.50+55.5%+62.9%$828.27M$980,000.00-9.832Short Interest ↑DAWNDay One Biopharmaceuticals2.9913 of 5 stars$8.16-5.9%$34.57+323.7%-48.1%$827.06M$131.16M-7.9260Analyst ForecastCOGTCogent Biosciences2.4137 of 5 stars$7.25-1.9%$14.43+99.0%+1.4%$825.41MN/A-2.9280Positive NewsXERSXeris Biopharma3.2728 of 5 stars$5.22+3.8%$5.92+13.3%+176.0%$803.57M$203.07M-11.60290High Trading VolumeGYREGyre Therapeutics0.2041 of 5 stars$8.57-30.2%N/A-48.1%$801.48M$105.03M0.0040News CoverageHigh Trading Volume Remove Ads Related Companies and Tools Related Companies PAHC Alternatives ZYME Alternatives EOLS Alternatives PHVS Alternatives AVDL Alternatives OCS Alternatives DAWN Alternatives COGT Alternatives XERS Alternatives GYRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYBT) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZYBT Stock Free ZYBT Stock Alerts